证 券 研 究 报 告 [Table增_R持at（ing维] 持） | [行Ta业ble_Industry] : | 医药生物 | | --- | --- | | 日期: | 2026年02月26日 shzqdatemark | | [T分ab析le师_Author] : | 张林晚 | | Tel: | 021-53686155 | | E-mail: | zhanglinwan@shzq.com | 《诺华 siRNA 降脂药物在华获批新适应 症，关注 PCSK9 及小核酸赛道》 《并购与授权合作持续活跃，关注创新药 领域资源整合加速》 ——2026 年 01 月 23 日 《产业化进程加速，脑机接口发展进入快 车道》 重点任务方面，《实施方案》提出6个方面共15项任务，包括：在实施 原料提质稳供行动方面，建设高标准中药原料生产基地，提升产地初 加工水平，提升关键技术和质量标准水平；在实施协同创新攻关行动 方面，健全协同创新体系，深度赋能中药新药研发；在实施制造能力 提升行动方面，提升中药饮片集约化生产水平，提升中药制造数智化 绿色化水平，优化全流程质量追溯体系；在实施民族药产业振兴行动 方面，大力发掘民 ...

证 券 研 究 报 告 [Table增_R持at（ing维] 持） | [行Ta业ble_Industry] : | 医药生物 | | --- | --- | | 日期: | 2026年02月26日 shzqdatemark | | [T分ab析le师_Author] : | 张林晚 | | Tel: | 021-53686155 | | E-mail: | zhanglinwan@shzq.com | 《诺华 siRNA 降脂药物在华获批新适应 症，关注 PCSK9 及小核酸赛道》 《并购与授权合作持续活跃，关注创新药 领域资源整合加速》 ——2026 年 01 月 23 日 《产业化进程加速，脑机接口发展进入快 车道》 产业链体系持续完善、板块业绩回暖在望，关 注中药高质量发展 ——医药生物行业周报（20260209-0213） [Tab主le_要Su观mm点ary] 中药高质量发展方案发布，产业链协同体系持续完善。近期，工业和 信息化部等八部门关于印发《中药工业高质量发展实施方案（2026— 2030年）》（以下简称《实施方案》）。《实施方案》指出，加快中 药工业结构优化和转型升级，全面提升中药工业产业 ...

Investment Rating - The industry rating is "Outperform the Market" [8] Core Insights - The top-level policy for traditional Chinese medicine (TCM) has been clarified, emphasizing high-quality development and supporting industry leaders. The "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" was released on February 6, 2026, outlining the development framework for the next five years. The plan highlights the importance of leading companies and innovation in driving industry growth [5][16][21]. - The TCM sector is expected to experience a turning point due to policy support, improved consumer environment, declining raw material prices, and inventory clearance. Key companies to watch include brand TCM firms like China Resources Sanjiu, Dong-E E-Jiao, Jiangzhong Pharmaceutical, and Mayinglong, as well as innovative TCM drug companies like Yiling Pharmaceutical and Fangsheng Pharmaceutical [5][22]. Market Review - In the week from February 2 to February 6, 2026, the CITIC Pharmaceutical Index rose by 0.3%, outperforming the CSI 300 Index by 1.7 percentage points, ranking 12th among CITIC's primary industry classifications. Since the beginning of 2026, the CITIC Pharmaceutical and Biotech sector index has increased by 3.3%, also outperforming the CSI 300 Index by 3.0 percentage points, ranking 19th [4][25]. - The top five performing stocks during this week were: Guangshentang (+29.8%), Haixiang Pharmaceutical (+18.6%), Meidixi (+18.0%), Tianzhihang (+17.6%), and Saike Xide (+14.5%) [4][39]. Short-term Investment Thoughts - The pharmaceutical sector has shown signs of recovery after a period of adjustment, with market sentiment expected to reverse around the Spring Festival. The performance of traditional Chinese medicine has been particularly strong, likely due to the recent policy announcements. The report suggests focusing on innovative drugs, medical devices, and companies benefiting from domestic demand [6][22]. - Recommended stocks for February include Heng Rui Medicine, Kangfang Biotech, Baiji Shenzhou, Ying'en Biotech, Tiger Medical, Microelectrophysiology, Huana Pharmaceutical, and Haite Biotech [6][12].

Group 1 - The core event of the news is the completion of the "Old People's Traceability - Yunnan Baiyao" initiative, which aims to enhance public trust in the quality of traditional Chinese medicine through a transparent supply chain [1] - A strategic cooperation signing ceremony was held between Yunnan Baiyao and Lao Baixing Pharmacy in Kunming, focusing on creating a new blueprint for the pharmaceutical health industry [1] - The traceability initiative involved a thorough verification of the ecological planting environment and standardized management processes in the core production area of Sanqi in Wenshan [1] Group 2 - The traceability event utilized a Douyin micro-variety live broadcast format, attracting over 100,000 viewers and effectively communicating the value of traceability [1] - Yunnan Baiyao employs a proprietary seed bank to cultivate high-activity seedlings, ensuring the quality of traditional medicine from the source [2] - The partnership aims to expand from Sanqi to other traditional Chinese medicine categories, focusing on high-quality development and innovative pharmaceutical services [2]

Core Viewpoint - The financial report of traditional Chinese medicine company Darentang (600329.SH) reveals a paradox of declining revenue and soaring profits, raising concerns about its core product growth and innovation capabilities amid industry challenges [1] Financial Performance - Darentang reported a revenue of 2.651 billion yuan, a year-on-year decline of 33.15%, while net profit surged by 193.08% to 1.928 billion yuan [1] - The profit increase was largely driven by non-recurring gains from the sale of Tianjin Shike equity, contributing 1.332 billion yuan; excluding this, the adjusted net profit grew by only 12.86% to 596 million yuan [2] - The revenue drop was primarily due to the strategic divestment of the pharmaceutical commercial sector, which accounted for over 30% of revenue [2] Business Structure and Product Performance - The industrial segment showed resilience with a revenue of 2.645 billion yuan, a slight increase of 0.87%, compensating for the loss from the commercial sector [2] - Key products like Suoyao Jiuxin Wan generated sales of 1.128 billion yuan, up 5.45%, while Qingyan Dingwan saw a remarkable growth rate of 52.28%, reaching sales of 289 million yuan [2] R&D and Innovation Challenges - Despite a 31.94% increase in R&D spending to 61.55 million yuan, the output of innovative products remains limited, with only two national-level traditional Chinese medicines in the pipeline [3] - The company is attempting cross-industry innovation with the launch of "Shuyuan Anfu series" skincare products, but this segment currently contributes less than 5% to total revenue [3] Quality Control and Policy Environment - The year 2025 is significant for the traditional Chinese medicine industry, with new policies aimed at enhancing quality control [4] - Darentang has improved its self-sufficiency in core medicinal materials from 35% in 2023 to 48% in mid-2025, with a quality inspection pass rate of 99.7% [4] Brand and Channel Strategy - The company has intensified brand-building efforts, conducting over 200 promotional events and increasing the proportion of young consumers to 28% [5] - Channel expansion has been a focus, with the coverage of grassroots medical institutions rising from 62% to 71%, although this has led to increased sales costs [6] Market Outlook and Challenges - Analysts express concerns about Darentang's core competitiveness, highlighting three main challenges: slowing growth of key products, lagging innovation in drug development, and the need for the health business to achieve scale [7] - The company's future success will depend on the progress of innovative drug development, the maturity of the health business model, and the ability to offset rising costs through increased sales from expanded channels [7]

Core Insights - The report highlights the positive performance of the pharmaceutical index, with five out of six sub-industries recording positive returns this week [2] - The approval of the traditional Chinese medicine "Loquat Lung Clearing Granules," developed by Xiamen University and Shenwei Pharmaceutical, marks a significant achievement in the modernization of traditional medicine, showcasing the integration of ancient wisdom with modern technology [3][8] - The Chinese traditional medicine industry is entering a new phase of high-quality development, supported by government policies and technological innovations, with the market size expected to exceed 480 billion yuan by 2024 [9][10] Industry Performance Review - The pharmaceutical sector, particularly the chemical pharmaceuticals and traditional Chinese medicine sub-industries, showed strong performance with increases of 5.01% and 3.12% respectively [14] - The valuation levels for the chemical pharmaceuticals and biological products were the highest at 92.95 times and 74.63 times respectively, while traditional Chinese medicine had a valuation of 34.05 times [14] Industry Trends and Developments - The report discusses the implementation of the "Strong Foundation Project" by the National Development and Reform Commission, aimed at enhancing grassroots healthcare services and promoting the integration of traditional Chinese medicine into the healthcare system [21] - The introduction of policies in Henan Province to include suitable traditional Chinese medicine techniques in medical insurance coverage is expected to alleviate the economic burden on patients and promote the use of traditional medicine in chronic disease treatment [26][30]

Core Viewpoint - The article discusses the significant impact of centralized procurement policies on the traditional Chinese medicine (TCM) industry, highlighting the challenges and potential restructuring within the sector as it enters a new era of competition and pricing pressures [1][2][3]. Group 1: Impact of Centralized Procurement - The centralized procurement system has greatly affected the Western medicine industry, and similar pressures are now being felt in the TCM sector as it officially enters the "procurement era" [1][3]. - The scope of centralized procurement for TCM has expanded from 15 provinces to nationwide, with the number of products increasing to 45, indicating a growing impact on the industry [10][9]. - Many selected companies are pricing their products close to cost, leading to expectations of profit declines in the TCM industry by 2025 [11][12]. Group 2: Market Dynamics and Price Trends - Despite the challenges, the price of raw materials for TCM has significantly decreased this year, with the Chinese herbal medicine price index dropping over 20% from its peak [14][13]. - Some companies that won bids in the procurement process are experiencing unexpectedly high profits due to fixed hospital procurement prices, leading to optimistic sales forecasts [17]. - The average price drop for selected products in the latest procurement round was 47.38%, with some products seeing reductions as high as 69.3% [37][38]. Group 3: Industry Restructuring and Future Outlook - The TCM industry is expected to undergo significant restructuring, with a potential reduction in the number of suppliers as centralized procurement becomes more prevalent [23][24]. - The government has issued policies aimed at enhancing the quality and development of the TCM industry, indicating a push towards modernization and improved standards [25]. - The performance of TCM companies has been under pressure, with a reported 4.6% decline in total revenue and an 18.7% drop in net profit for 75 listed TCM companies in 2024 [29][28]. Group 4: Competitive Landscape - The competitive landscape is shifting, with traditional TCM giants facing challenges as their unique product strategies are tested by centralized procurement [33][40]. - Companies that previously opted out of insurance reimbursement to avoid price cuts are now facing increased pressure as more exclusive products enter centralized procurement [34][36]. - The article suggests that only companies with strong R&D capabilities, unique products, and brand advantages will thrive in the increasingly competitive environment [44][42].

Core Viewpoint - The article discusses the significant impact of centralized procurement policies on the traditional Chinese medicine (TCM) industry, highlighting the challenges and potential restructuring within the sector due to these changes [1][2][21]. Group 1: Impact of Centralized Procurement - The centralized procurement system has greatly affected the Western medicine industry, and similar pressures are now being felt in the TCM sector as it enters the "procurement era" [1][3]. - The scope of centralized procurement for TCM has expanded from 15 provinces to nationwide, with the number of products increasing to 45, indicating a growing impact on the industry [10]. - Many companies that won bids in the procurement process are now pricing their products close to cost, leading to expectations of profit declines in the TCM industry by 2025 [11][12]. Group 2: Market Dynamics and Price Trends - The price index for TCM raw materials peaked in July 2024 and has since dropped over 20%, which has positively affected the profit margins of some winning companies in the procurement process [13][15]. - Some companies, such as Zhaoli Pharmaceutical, are optimistic about their performance in 2024, expecting significant sales growth despite lower bid prices [15]. - The centralized procurement process is expected to lead to a reduction in the number of TCM suppliers, with larger companies likely to gain market share due to their scale and brand influence [20]. Group 3: Financial Performance of TCM Companies - In 2024, the total revenue of 75 listed TCM companies decreased by 4.6%, with net profits down by 18.7%, reflecting the financial strain on the industry [26]. - Major players like Baiyunshan have seen revenue declines, indicating the challenges faced by traditional TCM giants [28]. - The trend of independent TCM products entering centralized procurement is increasing, with significant price reductions observed, such as a 69.3% drop for a product from Guangzhou Baiyunshan [34]. Group 4: Future Outlook and Industry Restructuring - The ongoing centralized procurement policies are expected to accelerate the restructuring of the TCM industry, with many companies facing potential mergers or exits from the market [39]. - The National Medical Insurance Administration plans to expand procurement alliances, which will further challenge companies lacking cost advantages [37]. - Companies with strong R&D capabilities and unique products are likely to thrive in the increasingly competitive environment [41].